Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
Clinical trial NCT02826434 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02826434
- Sponsor
- Massachusetts General Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-08-18
- Primary completion
- 2026-12-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.